Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the non-small-cell lung cancer drug market in Brazil will reach $240 million by 2014. Factors fuelling this growth include a slight but steady annual increase in the number of incident cases, greater uptake of higher-priced brands of chemotherapy, targeted regimens and maintenance treatment (all in the advanced setting) and modest uptake of novel targeted agents.

"Through the Brazilian national health system, virtually all diagnosed patients have access to treatment. However, a small but lucrative segment of patients with private health insurance largely drives the use of premium-priced novel chemotherapy and targeted agents," stated Decision Resources' Analyst Janie Cox, Ph.D. "During our 2009 - 2014 study period of Brazil's non-small-cell lung cancer drug market, collective sales of targeted therapies such as Roche's Avastin and Tarceva, and AstraZeneca's emerging agent Iressa, are expected to grow 21 percent annually while sales of Eli Lilly's novel chemotherapy agent, Alimta, are expected to grow 15 percent annually."

The new Emerging Markets report entitled Non-Small-Cell Lung Cancer in Brazil also finds that overall, drugs manufactured by Western drug companies accounted for approximately 60 percent of total 2009 non-small-cell lung cancer sales in Brazil. Although Eli Lilly and Roche dominated the market, generics leader Sandoz do Brasil seized a respectable market share. Increasing competition from non-originator products through the 2009 - 2014 forecast period will be offset by newly launched and patent-protected Western brands, such that Western drug companies' sales will rise to 70 percent in 2014. Non-originator products refer to Brazilian manufactured brands and Western or Brazilian generics.

The new report features extensive primary research of physicians and epidemiology study, with analysis of trends in major Brazilian cities--Rio de Janeiro, São Paulo, Brasilia, Belo Horizonte, Curitiba and Salvador--and the country overall.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Christopher Comfort   Decision Resources   781-296-2597   ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, +1-781-296-2597,
ccomfort@dresources.com

Russia's Breast Cancer Drug Market Will Reach $226 Million By 2014

View Now